Altasciences announced that it was recently recognized as a top-performing contract development and manufacturing organization in the area of Small Molecule Dosage Form in North America, based on industry research and feedback from sponsors.

Altasciences pharmaceutical dosage form services include tablets, liquid- and powder-filled capsules, over-encapsulated capsules, nanomilled suspensions, spray-dried dispersions, creams, gels, powders, and terminally sterilized injectables.

“This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” said Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are grateful for the opportunity to partner with esteemed sponsors from around the globe, providing them with integrated solutions that not only support groundbreaking therapeutic progress but also contribute meaningfully to getting those therapies to those who need them, faster.”

Altasciences’ CDMO facility supports drug development, from early-phase formulation to late-phase scale-up and commercial manufacturing. The company works to ensure batch consistency through in-house analytical testing and environmental monitoring. By providing integrated services and utilizing in-house expertise, Altasciences provides services to help accelerate the formulation, manufacture, and analysis processes to expedite the transition from preclinical to clinical phases.